Marker Therapeutics, Inc. (MRKR) Q1 2026 Earnings
MRKR·Reported May 15, 2026·After market close
Diluted EPS came in at $-0.16 (+40.7% YoY), beat the $-0.18 consensus by $0.02.
Diluted EPS
$-0.16beat by $0.02
Consensus: $-0.18
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Marker Therapeutics, Inc.'s Q1 2026 earnings report.
Marker Therapeutics, Inc. (MRKR) reported Q1 2026 earnings on May 15, 2026 after market close.
Marker Therapeutics, Inc. reported diluted EPS of $-0.16 for Q1 2026.
EPS beat the consensus estimate of $-0.18 by $0.02.
Compared to the same quarter a year prior, diluted EPS grew 40.7% from $-0.27.
You can read the 10-Q periodic report (0001104659-26-062763) directly on SEC EDGAR. The filing index links above go to sec.gov.